Glaukos (GKOS) AI Stock Analysis

• Market Cap: $4.46B
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 26.70%
• EPS Growth: 48.19%
• Country: US
• Employees: 995
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 57,349,987
• 10 Day Avg. Volume: 1,623,992
• 30 Day Avg. Volume: 1,065,714
• PEG Ratio: 150.23
• Price to Book (P/B): 10.31
• Price to Sales (P/S): 20.63
• P/FCF Ratio: -116.98
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $120.60
• Price Target Upside: 56.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 46 Neutral
• Price Target: $78.00 ▲(1.18% Upside)

Glaukos's overall stock score is primarily impacted by its strong revenue growth and strategic advancements, as highlighted in the earnings call. However, significant challenges in profitability, cash flow management, and a bearish technical outlook weigh heavily on the score. The negative P/E ratio and lack of dividend yield further contribute to a lower valuation score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, which supports long-term business expansion.

Innovation and Product Development

Continued innovation in product development enhances competitive advantage and positions Glaukos as a leader in ophthalmic solutions.

Strong Financial Position

Maintaining a strong cash position provides financial flexibility for strategic investments and operational stability.

Negative Factors

Profitability Challenges

Ongoing profitability issues can hinder long-term growth and limit the ability to reinvest in business development.

Regulatory and Reimbursement Risks

Regulatory changes and reimbursement reductions could negatively impact revenue and profitability in key markets.

Corneal Health Franchise Challenges

Challenges in the Corneal Health franchise may affect revenue diversification and growth potential in this segment.

Glaukos Business Overview & Revenue Model

Company Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

How the Company Makes Money

Glaukos generates revenue primarily through the sale of its surgical devices and related products for the treatment of glaucoma. The company's key revenue streams include the direct sales of its iStent and iStent inject devices, as well as revenue from related consumables and accessories. Glaukos also benefits from strategic partnerships with ophthalmology clinics and hospitals, which help to expand its market reach and distribution capabilities. Additionally, the company may explore partnerships with other healthcare organizations for product development, clinical studies, and co-marketing agreements, contributing to its overall revenue growth. As the prevalence of glaucoma and the demand for innovative treatment options increase, Glaukos is positioned to capitalize on these trends within the ophthalmic market.

Glaukos Financial Statement Overview

Summary

Glaukos demonstrates strong revenue growth and efficient production, but profitability remains a significant challenge due to high operating expenses. The balance sheet shows controlled leverage, yet negative returns on equity persist. Cash flow issues are evident, with negative operating and free cash flows, indicating a need for improved cash management strategies.

Income Statement

Glaukos shows a consistent revenue growth trend, with a 7.03% increase in TTM. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins. The gross profit margin remains strong, indicating efficient production, but high operating expenses are impacting overall profitability.

Balance Sheet

The balance sheet reflects a stable debt-to-equity ratio, improving from previous years, which indicates controlled leverage. However, the return on equity remains negative, highlighting ongoing profitability challenges. The equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a significant decline in free cash flow growth. The free cash flow to net income ratio is positive, suggesting some efficiency in cash generation relative to net income, but overall cash flow remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	432.95M	383.48M	314.71M	282.86M	294.01M	224.96M
Gross Profit	330.52M	289.45M	239.14M	213.88M	227.38M	133.24M
EBITDA	-62.19M	-77.63M	-82.12M	-48.76M	-1.47M	-83.59M
Net Income	-92.79M	-146.37M	-134.66M	-99.19M	-49.59M	-120.35M
Balance Sheet
Total Assets	986.96M	974.76M	940.41M	1.00B	1.05B	1.01B
Cash, Cash Equivalents and Short-Term Investments	274.79M	318.92M	295.43M	352.69M	414.05M	404.37M
Total Debt	105.02M	105.87M	383.74M	382.48M	382.38M	270.81M
Total Liabilities	221.85M	207.82M	478.65M	472.38M	462.55M	338.05M
Stockholders Equity	765.11M	766.93M	461.77M	530.00M	587.15M	667.45M
Cash Flow
Free Cash Flow	-26.92M	-67.62M	-78.01M	-63.35M	-23.08M	-29.92M
Operating Cash Flow	-20.62M	-61.32M	-57.76M	-33.08M	24.71M	-22.99M
Investing Cash Flow	-15.38M	47.83M	14.10M	44.78M	-58.23M	-205.06M
Financing Cash Flow	73.98M	91.54M	15.04M	6.25M	39.26M	262.54M

Glaukos Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 77.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GKOS, the sentiment is Negative. The current price of 77.09 is below the 20-day moving average (MA) of 81.94, below the 50-day MA of 85.47, and below the 200-day MA of 101.70, indicating a bearish trend. The MACD of -2.61 indicates Positive momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 21.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GKOS.

Glaukos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	―	$1.46B	21.95	19.29%	―	40.98%	34.80%
ITGR	―	$2.29B	27.34	5.18%	―	7.81%	-26.32%
IRTC	―	$5.95B	-63.11	-91.13%	―	22.37%	31.14%
LIVN	―	$2.91B	-13.70	-17.87%	―	8.57%	-1154.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	―	$1.02B	―	-111.91%	―	25.84%	-47.67%
GKOS	―	$4.46B	―	-12.98%	―	26.70%	48.19%

Glaukos Corporate Events

Glaukos Highlights Innovation in Recent Investor Presentation

Glaukos Corporation’s recent investor presentation highlights its strategic focus on innovation and commercial excellence, aiming to improve standards of care in ophthalmology. The company is advancing its iDose TR therapy, a groundbreaking sustained-release drug delivery system for glaucoma, which is expected to enhance patient compliance and outcomes by reducing reliance on traditional topical medications.

The most recent analyst rating on (GKOS) stock is a Buy with a $139.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.

Glaukos Corp. Reports Record Growth Amid Challenges

Glaukos Corp. recently held its earnings call, revealing a generally positive sentiment driven by strong financial performance and strategic advancements. The company reported record net sales and significant growth in key segments, such as the U.S. glaucoma franchise and international markets. Despite these achievements, challenges persist, including the impact of MAC LCDs on the MIGS market and potential disruptions from proposed CMS reimbursement changes. Nevertheless, the company’s positive achievements and strategic advancements appear to outweigh these challenges.

Glaukos Corporation Reports Strong Q2 2025 Growth

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) and continues to expand its portfolio with novel, dropless platform technologies.

Glaukos Reports Record Q2 Sales, Raises 2025 Guidance

On July 30, 2025, Glaukos Corporation announced its financial results for the second quarter ended June 30, 2025, reporting record net sales of $124.1 million, a 30% increase year-over-year. The company also raised its 2025 net sales guidance, reflecting strong growth driven by strategic execution and advancements in its pipeline of novel, dropless platform technologies aimed at improving patient outcomes in chronic eye diseases.

The most recent analyst rating on (GKOS) stock is a Buy with a $131.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.